课题基金 / 基金详情

EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES

EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
东部肿瘤合作组 - 威斯康星州研究
批准号:
8465828
负责人:
Brad Kahl
金额:
$49.69万
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-06-01 至 2015-02-28

项目摘要

项目成果

Brad Kahl的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请寻求支持东部合作肿瘤学小组(ECOG)在华盛顿大学保罗·P·卡伯恩综合癌症中心(UWCCC)的活动。在过去的30年里,UWCCC一直保持着模范的主要机构收益和强大的附属机构参与,同时提供高质量的数据和关键的科学领导地位。机构评估始终将威斯康星州大学ECOG项目在应计、行政和科学领导能力类别中排名靠前或接近靠前。UWCCC的基础、转化和临床研究计划旨在通过改善癌症的预防、早期发现和治疗来减少人口的癌症负担。UWCCC对癌症护理和研究的承诺从未像现在这样强烈。在当前的拨款周期中,我们的临床空间增加了两倍,研究空间增加了一倍,相当于近1亿美元的机构承诺,并将我们专注于癌症的教职员工增加了近50%。UWCCC的教职员工认为NCI合作小组是抗击癌症的战争中必不可少的组成部分。将科学发现转化为人类群体和个别患者,需要及时进行大规模临床试验的能力。经社理事会提供了这一重要论坛,世界妇女联合会将继续高度致力于其与经社理事会的互利伙伴关系。
英文摘要
DESCRIPTION (provided by applicant): This application seeks support for the activities of the Eastern Cooperative Oncology Group (ECOG) at the UW Paul P. Carbone Comprehensive Cancer Center (UWCCC). Over the past 30 years, the UWCCC has maintained exemplary main institution accrual and strong affiliate participation while providing high quality data and key scientific leadership. Institutional evaluations consistently rank the UW ECOG program at or near the top in categories of accrual, administrative, and scientific leadership. The basic, translational, and clinical research programs of the UWCCC are designed to reduce the cancer burden on the population by improving prevention, early detection, and treatment of cancer. The UWCCC commitment to cancer care and research has never been stronger. During the current grant cycle, we have tripled our clinical space and doubled our research space, representing an institutional commitment of nearly $100 million, and increased our cancer focused faculty by nearly 50%. The UWCCC faculty views the NCI cooperative groups as essential components in the war on cancer. Translation of scientific discovery to human populations and to individual patients requires an ability to conduct large scale clinical trials in a timely fashion. ECOG provides this vital forum and the UWCCC remains highly committed to its mutually beneficial partnership with ECOG.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
Potential role of polyribonucleotides in human neoplastic diseases.
多核糖核苷酸在人类肿瘤疾病中的潜在作用。
DOI: --
发表时间: 1985
期刊: Journal of biological response modifiers
影响因子: --
作者: [Borden,EC, Verma,AK, Wolberg,WH]
通讯作者: Wolberg,WH
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
amonafide、caracemide 和高三尖杉酯碱治疗晚期肾细胞癌患者的 II 期试验。
DOI: 10.1007/bf00180819
发表时间: 1996
期刊: Investigational new drugs
影响因子: 3.4
作者: [Witte,RS, Hsieh,P, Elson,P, Oken,MM, Trump,DL]
通讯作者: Trump,DL
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
阿霉素和紫杉醇加粒细胞集落刺激因子治疗转移性乳腺癌的 II 期试验:东部肿瘤合作组研究。
DOI: 10.1200/jco.1999.17.12.3828
发表时间: 1999
期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子: --
作者: [Sparano,JA, Hu,P, Rao,RM, Falkson,CI, Wolff,AC, Wood,WC]
通讯作者: Wood,WC
DOI: 10.1093/jnci/88.24.1828
发表时间: 1996-12
期刊: Journal of the National Cancer Institute
影响因子: --
作者: [D. Tormey;R. Gray;H. Falkson]
通讯作者: D. Tormey;R. Gray;H. Falkson
22
    Phase I Study of Rituximab with L2-7001 (Aldesleukin) for Non-Hodgkin's Lymphoma
    • 批准号:
      7043907
    • 项目类别:
    • 资助金额:
      $2.08万
    • 财政年份:
      2003
    • 负责人:
      Brad Kahl
    • 依托单位:
    EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
    • 批准号:
      7661563
    • 项目类别:
    • 资助金额:
      $62.1万
    • 财政年份:
      1978
    • 负责人:
      Brad Kahl
    • 依托单位:
    EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
    • 批准号:
      8284229
    • 项目类别:
    • 资助金额:
      $56.44万
    • 财政年份:
      1978
    • 负责人:
      Brad Kahl
    • 依托单位:
    EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
    • 批准号:
      7426841
    • 项目类别:
    • 资助金额:
      $61.06万
    • 财政年份:
      1978
    • 负责人:
      Brad Kahl
    • 依托单位:
    海外基金